Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Arab, Juan Pablo; Dirchwolf, Melisa; Álvares‐da‐Silva, Mário Reis; Barrera, Francisco; Benítez, Carlos; Castellanos-Fernandez, Marlene; Castro-Narro, Graciela; Chávez-Tapia, Norberto C.; Chiodi, Daniela; Cotrim, Helma Pinchemel; Cusi, Kenneth; Oliveira, Cláudia Pinto Marques Souza de; Díaz, José Alfredo Jáuregui; Fassio, E; Gerona, Solange; Girala, Marcos; Hernández, Nelia; Marciano, Sebastián; Masson, Walter; Méndez-Sánchez, Nahúm; Leite, Nathalie C.; Lozano, Adelina; Padilla, Martín; Panduro, Arturo; Paraná, Raymundo; Parise, Edison Roberto; Pérez, M Soledad; Poníachik, Jaime; Restrepo, Juan Carlos; Ruf, Andrés E.; Silva, Marcelo; Tagle, Martín; Tapias, Mónica; Torres, Kenia Urra; Vilar-Gómez, Eduardo; Gil, José Eduardo Costa; Gadano, Adrián; Arrese, Marco

doi:10.1016/j.aohep.2020.09.006

Cited by 98 publications

(124 citation statements)

References 135 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Further to standard assessment, which includes the use of biomarkers and imaging techniques as the initial step [36][37][38][39], the NAFLD diagnostic process should include a more accurate definition of a series of parameters mirroring the extent and severity of hepatic and extrahepatic involvement [40,41]. The recently proposed ''LDE system'' [42,43] is an example of a possible synthetic descriptor of variables related to the liver (L), to the determinants of disease specific to the individual patient (D), and to the extension of extrahepatic involvement (E) that is typical of a systemic disorder such as NAFLD [44].…”

Section: Diagnosismentioning

confidence: 99%

“…Principles of NAFLD management have been outlined in several clinical guidelines or position papers released and endorsed by either scientific societies or expert panels [ 36 – 38 ]. All these documents agree that lifestyle modifications remain the cornerstone of NAFLD management and are indicated in all patients [ 123 ].…”

Section: Tailoring Nafld Management To Individual Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Lonardo¹,

Arab

Arrese

2021

Adv Ther

Self Cite

View full text Add to dashboard Cite

Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/ MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Tailoring Nafld Management To Individual Patientsmentioning

confidence: 99%

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Lonardo¹,

Arab

Arrese

2021

Adv Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, studies from Mexico suggest a low burden of HBV-HCC. NAFLD is recognized as a major risk factor in the country and thus, it is responsible for a large number of cases with cirrhosis and HCC [18] . Although a large group of HCC cases are also related to alcohol-associated liver disease and HCV, HBV is only implicated in a small number of cases [19][20][21] .…”

Section: North Americamentioning

confidence: 99%

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Anugwom¹,

Allaire²,

Akbar³

et al. 2021

View full text Add to dashboard Cite

Hepatitis B infection (HBV) is one of the most common causes of hepatocellular carcinoma (HCC) worldwide. The age of occurrence, prognosis and incidence vary dramatically depending on the region of the world. This geographic variation is largely dependent on the contrasting incidence of HBV, age of transmission of the virus, the timing of integration into the human genome, and different HBV genotypes, as well as environmental factors. It results in a wide difference in viral interaction with the immune system, genomic modulation and the consequent development of HCC in an individual. In this review, we describe many factors implicated in HCC development, provide insight regarding at-risk populations and explain societal recommendations for HCC surveillance in persons living with HBV in different continents of the world.

show abstract

“…Non-alcoholic fatty lived disease (NAFLD) is considered the most common chronic liver disease, constituting a true epidemic. It affects between 20 to 30% of the world's population and an exponential increase in its prevalence is expected, accompanying the epidemic of metabolic syndrome, obesity and diabetes mellitus (DM) [1,2]. The prevalence in Uruguay is unknown [3].…”

Section: Introductionmentioning

confidence: 99%

Applicability of the New Criteria for Diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MALFD) in Patients with Non-Alcoholic Fatty Liver Disease

Martín¹,

Biliary²,

Romina³

et al. 2021

J Diabet Res Rev Rep

View full text Add to dashboard Cite

Introduction: Non-alcoholic fatty liver disease affects 1/3 to ¼ of the world’s population. Currently this pathology is being redefined by using the acronym MALFD (Metabolic Dysfunction-Associated Fatty Liver Disease) and the possibility of new criteria for its diagnosis is being discussed. Methodology: Prospective and descriptive studies carried out between July 2018 and June 2020 where the applicability of the new criteria in MAFLD diagnosis were valued. Patients with NAFLD (Non-alcoholic fatty liver disease) were enrolled in clinics specialized in this pathology. Results: Out of 172 patients enrolled, 96.4% (this represents a total of 165 patients) presented obesity, were over weighted and or presented Diabetes Mellitus. The rest of the patients (a total of 7) presented high blood pressure and or dyslipidemia. Moreover, it was observed that the higher the obesity index the higher the prevalence of Diabetes Mellitus. Conclusions: The criteria for the diagnosis of MAFLD are adaptable in patients with a diagnosis of NAFLD from the first consultation and allow the assessment of prognostic elements of the disease. This would allow us to intervene at very early stages which could impact patient’s prognosis

show abstract

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Cited by 98 publications

References 135 publications

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Applicability of the New Criteria for Diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MALFD) in Patients with Non-Alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About